The predictive value of serum galectin 3 for abdominal aortic calcification in maintenance hemodialysis patients: A prospective cohort study. Issue 2 (11th February 2020)

• Record Type: Journal Article
• Authors: Wang, Zhiyu; Chen, Zijin; Ma, Xiaobo; Yu, Haijin; Chen, Xiaonong
• Is Part Of: Hemodialysis international. Volume 24:Issue 2(2020)
• Page Start: 212
• Page End: 220
• Publication Date: 2020-02-11
• Subjects: End stage renal disease -- galectin 3 -- vascular calcification -- hemodialysis -- cohort study; Hemodialysis -- Periodicals; Renal Dialysis -- Periodicals; Renal Dialysis -- Congresses; Hemodialysis, Home -- Congresses; 617.461059
• DOI: 10.1111/hdi.12825
• Languages: English
• ISSNs: 1492-7535

Abstract

Abstract: Introduction: Heterotopic vascular calcification is a common complication of maintenance hemodialysis (MHD) patients. Galectin 3 (Gal‐3) has been reported to be associated with cardiovascular calcification. The current study aims to explore the potential predictive value of serum Gal‐3 for severe abdominal aortic calcification (AAC) and AAC progression in MHD patients. Methods: A prospective cohort who underwent hemodialysis during July 2014 at the Blood Purification Center of Ruijin Hospital were followed up for 3 years. Two AAC assessments were performed: one at baseline and one after the 3‐year follow‐up period. Serum Gal‐3 was detected with quantitative ELISA kits. SPSS 23.0 and MedCalc 11.4.2.0 were used to analyze the data. Findings: One hundred and fifty‐two patients were recruited. Approximately 59.9% were male, the median age was 60 (50–67) years. Logistic regression analysis indicated that serum Gal‐3 was an independent risk factor for both follow‐up severe AAC and AAC progression. Receiver operating characteristic (ROC) curve analysis revealed significant prognostic value of serum Gal‐3 for predicting severe AAC and AAC progression within 3 years. Discussion: We found serum Gal‐3 is correlated to vascular calcification in ESRD patients. Gal‐3 may be a potential biomarker of vascular calcification for MHD patients.